GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Cyclically Adjusted PS Ratio

Repligen (FRA:RGN) Cyclically Adjusted PS Ratio : 18.99 (As of Jun. 03, 2024)


View and export this data going back to . Start your Free Trial

What is Repligen Cyclically Adjusted PS Ratio?

As of today (2024-06-03), Repligen's current share price is €135.40. Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €7.13. Repligen's Cyclically Adjusted PS Ratio for today is 18.99.

The historical rank and industry rank for Repligen's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:RGN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.06   Med: 24.59   Max: 79.23
Current: 19.56

During the past years, Repligen's highest Cyclically Adjusted PS Ratio was 79.23. The lowest was 9.06. And the median was 24.59.

FRA:RGN's Cyclically Adjusted PS Ratio is ranked worse than
95.57% of 474 companies
in the Medical Devices & Instruments industry
Industry Median: 2.155 vs FRA:RGN: 19.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Repligen's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.463. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.13 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Repligen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Repligen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Cyclically Adjusted PS Ratio Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.76 55.67 55.59 27.21 24.68

Repligen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.59 20.62 22.42 24.68 24.13

Competitive Comparison of Repligen's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted PS Ratio falls into.



Repligen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Repligen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=135.40/7.13
=18.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Repligen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.463/131.7762*131.7762
=2.463

Current CPI (Mar. 2024) = 131.7762.

Repligen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.346 100.560 0.453
201409 0.356 100.428 0.467
201412 0.394 99.070 0.524
201503 0.575 99.621 0.761
201506 0.568 100.684 0.743
201509 0.524 100.392 0.688
201512 0.589 99.792 0.778
201603 0.673 100.470 0.883
201606 0.760 101.688 0.985
201609 0.641 101.861 0.829
201612 0.706 101.863 0.913
201703 0.832 102.862 1.066
201706 0.823 103.349 1.049
201709 0.721 104.136 0.912
201712 0.791 104.011 1.002
201803 0.820 105.290 1.026
201806 0.908 106.317 1.125
201809 0.926 106.507 1.146
201812 0.982 105.998 1.221
201903 1.160 107.251 1.425
201906 1.275 108.070 1.555
201909 1.217 108.329 1.480
201912 1.179 108.420 1.433
202003 1.297 108.902 1.569
202006 1.457 108.767 1.765
202009 1.494 109.815 1.793
202012 1.604 109.897 1.923
202103 2.110 111.754 2.488
202106 2.382 114.631 2.738
202109 2.641 115.734 3.007
202112 2.854 117.630 3.197
202203 3.186 121.301 3.461
202206 3.463 125.017 3.650
202209 3.538 125.227 3.723
202212 3.092 125.222 3.254
202303 2.990 127.348 3.094
202306 2.584 128.729 2.645
202309 2.323 129.860 2.357
202312 2.559 129.419 2.606
202403 2.463 131.776 2.463

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Repligen  (FRA:RGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Repligen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Repligen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (FRA:RGN) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Repligen (FRA:RGN) Headlines

No Headlines